The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 23, 2016
Filed:
Feb. 27, 2010
Stephen J. Haggarty, Dorchester, MA (US);
Daniel Fass, Winchester, MA (US);
Jennifer Pan, Acton, MA (US);
Josh Ketterman, Cambridge, MA (US);
Edward Holson, Newton Highlands, MA (US);
Tracey Lynn Petryshen, Cambridge, MA (US);
Michael C. Lewis, Boston, MA (US);
Stephen J. Haggarty, Dorchester, MA (US);
Daniel Fass, Winchester, MA (US);
Jennifer Pan, Acton, MA (US);
Josh Ketterman, Cambridge, MA (US);
Edward Holson, Newton Highlands, MA (US);
Tracey Lynn Petryshen, Cambridge, MA (US);
Michael C. Lewis, Boston, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
The General Hospital Corporation, Boston, MA (US);
Abstract
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.